BR0013416A - Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado - Google Patents

Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado

Info

Publication number
BR0013416A
BR0013416A BR0013416-3A BR0013416A BR0013416A BR 0013416 A BR0013416 A BR 0013416A BR 0013416 A BR0013416 A BR 0013416A BR 0013416 A BR0013416 A BR 0013416A
Authority
BR
Brazil
Prior art keywords
drug
group
bisphosphonate
treating
fractured bone
Prior art date
Application number
BR0013416-3A
Other languages
English (en)
Inventor
David Graham Little
Original Assignee
Royal Alexandra Hosp Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children
Publication of BR0013416A publication Critical patent/BR0013416A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DROGA, USO DE UMA DROGA SELECIONADA DO GRUPO QUE CONSISTE DE PELO MENOS UM BISFOSFONATO, E, MéTODO PARA TRATAMENTO DE UM OSSO FRATURADO". Um droga selecionada de um grupo que consiste de bisfosfonatos para promover o crescimento de osso e para o tratamento de uma fratura.
BR0013416-3A 1999-08-19 2000-08-17 Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado BR0013416A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Publications (1)

Publication Number Publication Date
BR0013416A true BR0013416A (pt) 2002-04-30

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013416-3A BR0013416A (pt) 1999-08-19 2000-08-17 Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado

Country Status (16)

Country Link
EP (1) EP1214079A4 (pt)
JP (1) JP2003507426A (pt)
KR (1) KR20020027562A (pt)
CN (1) CN100345548C (pt)
AU (1) AUPQ232599A0 (pt)
BR (1) BR0013416A (pt)
CA (1) CA2381302A1 (pt)
HK (1) HK1048441B (pt)
HU (1) HUP0202396A3 (pt)
IL (1) IL148166A0 (pt)
NO (1) NO20020784D0 (pt)
NZ (1) NZ517538A (pt)
PL (1) PL353485A1 (pt)
SK (1) SK2382002A3 (pt)
WO (1) WO2001013922A1 (pt)
ZA (1) ZA200202160B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL361909A1 (en) * 2001-02-06 2004-10-04 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1383509A4 (en) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children MEDICAMENT FOR USE IN BONE TRAINING
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
KR20060058134A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
ES2379485T3 (es) 2005-10-27 2012-04-26 Thommen Medical Ag Implante dental y procedimiento para su fabricación
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN114532937B (zh) * 2020-11-18 2024-11-01 中国人民解放军海军军医大学第一附属医院 一种小肠镜辅助装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
CZ282889B6 (cs) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. Použití difosfonátů a parathormonu pro výrobu léčiva, které se používá pro léčení osteoporosy
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
CA2151240A1 (en) * 1992-12-23 1994-07-07 Donna T. Whiteford Biophosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
EP1214079A1 (en) 2002-06-19
IL148166A0 (en) 2002-09-12
HUP0202396A2 (hu) 2002-11-28
NO20020784L (no) 2002-02-18
CN100345548C (zh) 2007-10-31
NO20020784D0 (no) 2002-02-18
KR20020027562A (ko) 2002-04-13
ZA200202160B (en) 2003-08-27
PL353485A1 (en) 2003-11-17
CA2381302A1 (en) 2001-03-01
JP2003507426A (ja) 2003-02-25
AUPQ232599A0 (en) 1999-09-09
HK1048441B (zh) 2008-02-22
CN1370071A (zh) 2002-09-18
NZ517538A (en) 2003-07-25
EP1214079A4 (en) 2004-03-24
HK1048441A1 (en) 2003-04-04
SK2382002A3 (en) 2002-09-10
HUP0202396A3 (en) 2005-02-28
WO2001013922A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BR0014767A (pt) Fibras de sementes de plantas e uso
IS1724B (is) Aðferð við meðhöndlun á ígræðlingi úr málmi fyrirskurðaðgerð
FI971974A0 (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
WO2002041837A3 (en) Treatment of mucositis
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
SE9901272D0 (sv) New improved formulation
EP1233770A4 (en) PHOSPHONATE COMPOUNDS
BG100910A (bg) Използване на бисфосфонати за инхибиране на костна резорбция след имплантиране на ортопедична протеза
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
ES2153076T3 (es) Agentes herbicidas basados en bencisoxazol y bencisotiazol sustituidos.
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
BR0112350A (pt) Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
PA8452701A1 (es) Agonistas de prostaglandinas
DE60233803D1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
BR0212757A (pt) Composição, método para produzir uma composição de fator de crescimento, e, método para tratar um defeito de osso, tendão ou cartilagem
BR9811643A (pt) Suplementação quìmica de osso
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI NO 2011 DE 21/07/2009.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13, 10(VIII), 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.